{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T05:25:01.210108+00:00","company":{"ticker":"ARTL","cik":1621221,"company_name":"ARTELO BIOSCIENCES, INC."},"pagination":{"limit":100,"returned":12,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"30a773793f4788ba27e0717a0e686a738631fca3","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain accredited investors","effective_date":"2026-03-27","item_codes_triggered":["1.01"],"value_text":"$10,996,902.70"},"claim":"ARTELO BIOSCIENCES, INC. entered into Purchase Agreement with certain accredited investors valued at $10,996,902.70 (effective 2026-03-27).","evidence_excerpt":"On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-26-000574","anchor_url":"https://secwatch.observer/filing/0001640334-26-000574#claim-30a773793f4788ba27e0717a0e686a738631fca3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000574/0001640334-26-000574-index.htm"},{"fact_type":"material_agreement","fact_key":"0821c4b3f99561217bab637bd98ccb0b0f8b69c4","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-03-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Labrys Fund II, L.P.","effective_date":"2026-03-20","item_codes_triggered":["1.01"],"value_text":"aggregate principal amount of $315,000.00"},"claim":"ARTELO BIOSCIENCES, INC. entered into Securities Purchase Agreement with Labrys Fund II, L.P. valued at aggregate principal amount of $315,000.00 (effective 2026-03-20).","evidence_excerpt":"On March 20, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of March 20, 2026 (the “Purchase Agreement”), with Labrys Fund II, L.P., a Delaware limited partnership (“Labrys”), pursuant to which the Company issued a 10% promissory note in the aggregate principal amount of $315,000.00, which includes an original issue discount of $15,000.00, for an aggregate purchase price of $300,000.00 (the “Note”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-26-000554","anchor_url":"https://secwatch.observer/filing/0001640334-26-000554#claim-0821c4b3f99561217bab637bd98ccb0b0f8b69c4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000554/0001640334-26-000554-index.htm"},{"fact_type":"material_agreement","fact_key":"ef5a1775b2300aa961507c84543095ff77e9e82f","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-03-18T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Boot Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Boot Capital LLC","effective_date":"2026-03-12","item_codes_triggered":["1.01"],"value_text":"$100,000.00"},"claim":"ARTELO BIOSCIENCES, INC. entered into Boot Purchase Agreement with Boot Capital LLC valued at $100,000.00 (effective 2026-03-12).","evidence_excerpt":"Additionally, on March 12, 2026, the Company entered into a Securities Purchase Agreement, dated as of March 12, 2026 (the “Boot Purchase Agreement” and together with the Vanquish Purchase Agreement, the “Purchase Agreements”), with Boot Capital LLC, a Delaware limited liability company (“Boot” and together with Vanquish , the “Buyers”), pursuant to which the Company issued a 12% bridge note in the aggregate principal amount of $113,000.00, which includes an original issue discount of $13,000.00, for an aggregate purchase price of $100,000.00 (the “Boot Note” and together with the Vanquish Note, the “Notes”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-26-000475","anchor_url":"https://secwatch.observer/filing/0001640334-26-000475#claim-ef5a1775b2300aa961507c84543095ff77e9e82f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000475/0001640334-26-000475-index.htm"},{"fact_type":"material_agreement","fact_key":"257cd320d137e422b59ad1392c71264832da6e30","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-03-18T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Vanquish Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Vanquish Funding Group Inc.","effective_date":"2026-03-12","item_codes_triggered":["1.01"],"value_text":"$210,000.00"},"claim":"ARTELO BIOSCIENCES, INC. entered into Vanquish Purchase Agreement with Vanquish Funding Group Inc. valued at $210,000.00 (effective 2026-03-12).","evidence_excerpt":"On March 12, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of March 12, 2026 (the “Vanquish Purchase Agreement”), with Vanquish Funding Group Inc., a Virginia corporation (“Vanquish”), pursuant to which the Company issued a 12% bridge note in the aggregate principal amount of $237,300.00, which includes an original issue discount of $27,300.00, for an aggregate purchase price of $210,000.00 (the “Vanquish Note”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-26-000475","anchor_url":"https://secwatch.observer/filing/0001640334-26-000475#claim-257cd320d137e422b59ad1392c71264832da6e30","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000475/0001640334-26-000475-index.htm"},{"fact_type":"governance_change","fact_key":"d7e9c7dc427ddbf42e8654e8a4ddc869baced91e","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-03-06T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-03-10","item_codes_triggered":["5.03"],"summary_text":"Effected a one-for-three reverse stock split of common stock and reduced authorized shares accordingly."},"claim":"ARTELO BIOSCIENCES, INC.: Effected a one-for-three reverse stock split of common stock and reduced authorized shares accordingly (effective 2026-03-10).","evidence_excerpt":"On March 5, 2026, Artelo Biosciences, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a Certificate of Change (the “Certificate of Change”), pursuant to Nevada Revised Statutes 78.209, to effect a one-for-three (1-for-3) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-26-000395","anchor_url":"https://secwatch.observer/filing/0001640334-26-000395#claim-d7e9c7dc427ddbf42e8654e8a4ddc869baced91e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000395/0001640334-26-000395-index.htm"},{"fact_type":"material_agreement","fact_key":"ee14d8130f8b121446a5f29193792d9e0142da54","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-02-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Equity Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Square Gate Capital Master Fund, LLC – Series 5","effective_date":"2026-01-30","item_codes_triggered":["1.01"],"value_text":"up to $25 million"},"claim":"ARTELO BIOSCIENCES, INC. entered into Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5 valued at up to $25 million (effective 2026-01-30).","evidence_excerpt":"On January 30, 2026, Artelo Biosciences, Inc. (the “Company”) entered into an Equity Purchase Agreement, dated as of January 30, 2026 (the “Purchase Agreement”), with Square Gate Capital Master Fund, LLC – Series 5, a series limited liability company organized in the state of Delaware (“Square Gate”), pursuant to which the Company has the right, but not the obligation, to direct Square Gate to purchase up to $25 million (the “Initial Commitment Amount”) in shares of common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-26-000227","anchor_url":"https://secwatch.observer/filing/0001640334-26-000227#claim-ee14d8130f8b121446a5f29193792d9e0142da54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000227/0001640334-26-000227-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"6e3b493ce64ac833932d3067c16409928fde927b","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2026-01-16T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2026-01-14","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5620(a)"],"rules_cited_in_text":true},"claim":"ARTELO BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).","evidence_excerpt":"January 14, 2026, the Company received a letter from the Staff of Nasdaq (the “Nasdaq Notice”) indicating that it is not in compliance with Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”), which requires companies listed on Nasdaq to hold an annual meeting of shareholders no later than one year after the end of the Company’s fiscal year-end, and, as a result, does not currently satisfy the Annual Meeting Rule. The Staff indicated in the Nasdaq Notice that the Company’s non-compliance with the Annual Meeting Rule could be an additional basis for a delisting determination. The Company ac","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-26-000109","anchor_url":"https://secwatch.observer/filing/0001640334-26-000109#claim-6e3b493ce64ac833932d3067c16409928fde927b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033426000109/0001640334-26-000109-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"c74063c18679d1b7e82a7f75cf8289b4dec6de27","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2025-11-25T23:59:59+00:00","payload":{"company_response":"Company intends to appeal to a hearing panel pursuant to Nasdaq Listing Rule 5800 Series","compliance_status":"delisting_pending","cure_deadline":"2025-11-26","deficiency_type":"stockholders_equity","delisting_effective_date":"2025-12-01","exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"stockholders' equity of at least $2,500,000","notice_date":"2025-11-19","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"Listing Rule 5550(b)(1)","reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"ARTELO BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"ndicated that unless the Company requests a hearing panel appeal of the delist determination by November 26, 2025, its securities would be delisted on December 1, 2025. The Company intends to appeal Nasdaq’s determination to a hearing panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any further delisting actions through the hearing or any extension the hearings panel provides. Following the appeal request, the Company’s common stock, par value $0.001 per share, will continue to trade on Nasdaq under the symbol “ARTL.” 2 SIGNATURES Pursuant to the requir","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-25-002210","anchor_url":"https://secwatch.observer/filing/0001640334-25-002210#claim-c74063c18679d1b7e82a7f75cf8289b4dec6de27","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425002210/0001640334-25-002210-index.htm"},{"fact_type":"governance_change","fact_key":"e73c8d5a223b8c39c8820fe67cb03b383e88b60d","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2025-11-14T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-11-10","item_codes_triggered":["5.03"],"summary_text":"Eliminated stockholder right to fill Board vacancies and provided that directors are elected by plurality vote"},"claim":"ARTELO BIOSCIENCES, INC.: Eliminated stockholder right to fill Board vacancies and provided that directors are elected by plurality vote (effective 2025-11-10).","evidence_excerpt":"On November 10, 2025, the board of directors (the “Board”) of Artelo Biosciences, Inc. (the “Company”) amended the Company’s amended and restated bylaws (the “Bylaws”), as provided in a Certificate of Amendment to Bylaws (the “Bylaws Amendment”), as follows: · The Bylaws have been updated to provide that the right of stockholders to fill vacancies in the Board has been eliminated; and · The Bylaws have been updated to provide that directors shall be elected at a meeting of the stockholders by a plurality of the votes cast at the election.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-25-002118","anchor_url":"https://secwatch.observer/filing/0001640334-25-002118#claim-e73c8d5a223b8c39c8820fe67cb03b383e88b60d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425002118/0001640334-25-002118-index.htm"},{"fact_type":"debt_financing","fact_key":"29dff323cbd27d417bb4b010d11a978f9ca8cb51","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2025-10-31T23:59:59+00:00","payload":{"counterparty":null,"effective_date":"2025-10-28","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"12% per annum","item_codes_triggered":["2.03"],"maturity_text":"six months after the closing of the Notes Offering","principal_text":"$690,154.69"},"claim":"ARTELO BIOSCIENCES, INC. incurred convertible notes of $690,154.69 at 12% per annum maturing six months after the closing of the Notes Offering.","evidence_excerpt":"On October 28, 2025, Artelo Biosciences, Inc. (the “ Company ”) entered into a Subscription Agreement (the “ Subscription Agreement ”) pursuant to which it issued and sold to certain investors (the “ Investors ”), and the Investors purchased (by converting all or a portion of the unconverted “Voluntary Conversion” portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the “ Notes ”) to the Investors in an aggregate principal amount of $690,154.69;","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-25-001930","anchor_url":"https://secwatch.observer/filing/0001640334-25-001930#claim-29dff323cbd27d417bb4b010d11a978f9ca8cb51","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425001930/0001640334-25-001930-index.htm"},{"fact_type":"governance_change","fact_key":"45a48c2bb9557a89b601436a47c6e575568a2f02","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2025-09-10T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-09-09","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to change special meeting notice period, eliminate stockholder action by written consent, clarify status as issuing corporation under NRS 78.378-78.3793, and set record date limit of 60 days."},"claim":"ARTELO BIOSCIENCES, INC.: Amended bylaws to change special meeting notice period, eliminate stockholder action by written consent, clarify status as issuing corporation under NRS 78.378-78.3793, and set record date limit of 60 days (effective 2025-09-09).","evidence_excerpt":"On September 9, 2025, the board of directors (the “Board”) of Artelo Biosciences, Inc. (the “Company”) amended the Company’s amended and restated bylaws, as provided in a Certificate of Amendment to Bylaws (the “Bylaws Amendment”), as follows: · The required notice period for special meetings of the Board has been updated, as provided in the Bylaws Amendment; · The right of stockholders to take action without a meeting has been eliminated; · The Bylaws have been updated to provide that the Company shall in all respects be considered an “issuing corporation” for purposes of the provisions of NRS 78.378 to 78.3793 inclusive, irrespective of whether the Company, as of any date, (i) has 200 or more stockholders of record, at least 100 of whom have had addresses in Nevada appearing on the stock ledger of the Company at all times during the 90 days immediately preceding such date, and/or (ii) does business in Nevada directly or through an affiliated corporation; and · The Bylaws have been up","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-25-001660","anchor_url":"https://secwatch.observer/filing/0001640334-25-001660#claim-45a48c2bb9557a89b601436a47c6e575568a2f02","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425001660/0001640334-25-001660-index.htm"},{"fact_type":"governance_change","fact_key":"036fb3fd1bf394d2746944e295fe569e42073e2e","cik":1621221,"ticker":"ARTL","company_name":"ARTELO BIOSCIENCES, INC.","filed_at":"2025-06-13T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-13","item_codes_triggered":["5.03"],"summary_text":"Effected a one-for-six reverse stock split of common stock and proportionally reduced authorized shares."},"claim":"ARTELO BIOSCIENCES, INC.: Effected a one-for-six reverse stock split of common stock and proportionally reduced authorized shares (effective 2025-06-13).","evidence_excerpt":"On June 12, 2025, Artelo Biosciences, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a Certificate of Change (the “Certificate of Change”), pursuant to Nevada Revised Statutes 78.209, to effect a one-for-six (1-for-6) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001640334-25-001046","anchor_url":"https://secwatch.observer/filing/0001640334-25-001046#claim-036fb3fd1bf394d2746944e295fe569e42073e2e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1621221/000164033425001046/0001640334-25-001046-index.htm"}]}